Ipsen outlines financial targets for 2011

Ipsen has outlined its financial and strategic targets for the 2011 fiscal year in its latest financial report.

The pharmaceutical company is anticipating a growth in specialty care drug sales of around eight percent this year compared to 2010, which will help to counterbalance the pressures faced by its primary care treatments unit.

Marc de Garidel, Ipsen's chairman and chief executive officer, stated that its promising drug portfolio will play a role in this, including currently available treatments and late-stage developmental compounds.

In addition, the company is also planning a strategic review of its assets during the coming months as it looks to determine a method of maximising its growth potential.

"Ipsen's development and growth rely on particularly solid fundamentals," said Mr de Garidel.

Last week, Ipsen announced that it has entered into a new theranostics-centred partnership with bioMerieux that will aim to expand access to personalised treatments for various forms of cancer.